Progress in health policies on CBD in Argentina and MERCOSUR

Vitor Nifoci and Cristian Emanuel Cabrera

SAP Health and Policy, 2024

Abstract: Cannabidiol (CBD), a compound derived from cannabis, was considered a promising therapeutic option for treating refractory epilepsy. It was shown that, when combined with conventional treatments, it significantly reduced seizures in syndromes such as Dravet, Lennox-Gastaut and Tuberous Sclerosis. In Argentina, its benefits were recognised and public policies were implemented to facilitate access, with the authorisation of the ANMAT and programmes of the Ministry of Health. At a regional level, MERCOSUR promoted joint strategies to improve access to high-cost medicines. However, serious adverse effects were observed, making strict medical supervision necessary. In general, CBD represented a relevant therapeutic alternative, although the need for further research into its safety and efficacy was emphasised.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://southam.pub/journals/files/shp/shp2024139en.pdf (application/pdf)
https://southam.pub/journals/files/shp/shp2024139es.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cwf:shpart:shp2024139

DOI: 10.56294/shp2024139

Access Statistics for this article

More articles in SAP Health and Policy from South American Publishing
Bibliographic data for series maintained by South American Publishing Journals Manager ().